(HealthDay)—In a case report published online June 29 in the Journal of Clinical Pharmacy and Therapeutics, nephrotic syndrome is diagnosed in a 32-year-old female with relapsed Hodgkin's lymphoma who was on everolimus ...
Jul 7, 2017
0
0
August 29, 2013) St. Jude Children's Research Hospital scientists have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to fashion a more effective ...
Aug 29, 2013
0
0
Huntsman Cancer Institute (HCI) researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard ...
Nov 30, 2012
0
0
Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment. Alectinib is a drug commonly ...
Jan 22, 2021
0
4
Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients' treatment with a novel class of targeted therapies, according to a University of North ...
Oct 3, 2016
0
6
(HealthDay)—The orally bioavailable tyrosine kinase inhibitor cabozantinib (XL184) has clinical activity in men with castration-resistant prostate cancer (CRPC), according to a study published online Nov. 19 in the Journal ...
Dec 3, 2012
0
0
A new editorial paper was published in Oncotarget, titled "Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors."
Nov 8, 2023
0
0
Diabetic nephropathy (DN) is a kidney disease characterized by loss of kidney function in patients with diabetes.
Oct 17, 2018
0
0
An interdisciplinary team of researchers from the University of Vienna (Institute of Inorganic Chemistry) and the Medical University of Vienna (Institute for Cancer Research) has successfully developed a new strategy for ...
Sep 26, 2014
0
0
A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor (TKI), axitinib, significantly improves progression-free survival (PFS) in previously untreated patients with advanced renal cell ...
Oct 22, 2018
0
0
